title: Safety of quetiapine fumarate extended release in the treatment of Korean patients with acute schizophrenia.
abstract: BACKGROUND
  The aim of this study was to evaluate the efficacy and safety of quetiapine fumarate extended release (XR) in the treatment of Korean subjects with acute schizophrenia.
  
  
  METHODS
  This was an 8-week, multi-center, open-label, non-comparative study to evaluate the efficacy and safety of quetiapine fumarate XR at a daily dose of 400-800 mg. Changes in total scores on the Positive and Negative Syndrome Scale (PANSS) from baseline to week 8 were analyzed to evaluate the efficacy of quetiapine XR. Additionally, the Clinical Global Impression scale and the Montgomery-Åsberg Depression Rating Scale were administered.
  
  
  RESULTS
  The mean change in PANSS total scores was -26.8, and the mean PANSS total score at the endpoint was significantly lower than that at baseline. The mean PANSS positive score, negative score, and general score showed statistically significant reductions at the end of the study. Statistically significant changes were also observed in Clinical Global Impression-Severity and Montgomery-Åsberg Depression Rating Scale scores. The most common treatment-related adverse events in the group receiving quetiapine XR were sedation (10.6%) and constipation (9.6%).
  
  
  CONCLUSIONS
  In this study of Korean patients with acute schizophrenia, quetiapine XR showed clinical efficacy and relatively good tolerability.
authors: Department of Psychiatry, Haeundae Paik Hospital and Paik Institute for Clinical Research, School of Medicine, Inje University, Busan, Korea.
authors: Jung-Goo
authors: JG
authors: Lee
authors: Jong-Il
authors: JI
authors: Lee
authors: Yang-Tae
authors: YT
authors: Kim
authors: Chul-Eung
authors: CE
authors: Kim
authors: Chang-Yoon
authors: CY
authors: Kim
authors: Jin-Sang
authors: JS
authors: Yoon
authors: So-Young
authors: SY
authors: Yoo
authors: Young-Hoon
authors: YH
authors: Kim
mesh_terms: D000208:Acute Disease; D000328:Adult; D014150:Antipsychotic Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D003692:Delayed-Action Preparations; D003987:Dibenzothiazepines / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D011569:Psychiatric Status Rating Scales; D000069348:Quetiapine Fumarate; D056910:Republic of Korea; D012559:Schizophrenia / Q000188:drug therapy* / Q000503:physiopathology; D012720:Severity of Illness Index; D016896:Treatment Outcome; D055815:Young Adult
chemical_list: D014150:Antipsychotic Agents; D003692:Delayed-Action Preparations; D003987:Dibenzothiazepines; D000069348:Quetiapine Fumarate